Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 268

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis

Iorga, Andrea, Dara, Lily, Kaplowitz, Neil·2017·International Journal of Molecular Sciences
DOI 10.3390/ijms18051018PMC PMC5454931
Open this paper in CoChat — free account

Abstract

Drug-induced liver injury (DILI) can broadly be divided into predictable and dose dependent such as acetaminophen (APAP) and unpredictable or idiosyncratic DILI (IDILI). Liver injury from drug hepatotoxicity (whether idiosyncratic or predictable) results in hepatocyte cell death and inflammation. The cascade of events leading to DILI and the cell death subroutine (apoptosis or necrosis) of the cell depend largely on the culprit drug. Direct toxins to hepatocytes likely induce oxidative organelle stress (such as endoplasmic reticulum (ER) and mitochondrial stress) leading to necrosis or apoptosis, while cell death in idiosyncratic DILI (IDILI) is usually the result of engagement of the innate and adaptive immune system (likely apoptotic), involving death receptors (DR). Here, we review the hepatocyte cell death pathways both in direct hepatotoxicity such as in APAP DILI as well as in IDILI. We examine the known signaling pathways in APAP toxicity, a model of necrotic liver cell death. We also explore what is known about the genetic basis of IDILI and the molecular pathways leading to immune activation and how these events can trigger hepatotoxicity and cell death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms18051018

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Tumor necrosis factor (TNF) receptor-mediated cell death. TNF binding to TNF receptor (TNFR) results in the formation of complex I which includes TNFR-associated death domain (TRADD), receptor interacting protein kinase-1 (RIPK1), TNFR-associated factor 2 (TRAF2), cellular inhibitor of apoptosis 1 (cIAP1), cellular inhibitor of apoptosis 2 (cIAP2) and linear ubiquitin chain assembly complex (LUBAC). RIPK1 is ubiquitinated resulting in the formation of a platform and recruitment of the IκB kinase (IKK) complex (NFκB Essential Modulator (NEMO), IKK1 and IKK2) and TAB (TAK1-binding protein)/TAK-1 (transforming growth factor-β-activated kinase 1) complexes. This results in the activation of NFκB and mitogen-activated protein kinase (MAPK). For apoptosis to occur, the cytoplasmic Complex II is formed which can have two forms. Complex IIa is made up of TRADD, FADD (fas-associated protein with death domain) and caspase-8 and complex IIb consists of RIPK1/RIPK3, FADD, caspase 8 and FLICE-like inhibitory protein long form (FLIPL). Complex II leads to caspase-8-mediated activation of caspase 3/7 and apoptosis in type I cells such as lymphocytes. In type II cells such as hepatocytes, caspase 8 mediates cleavage of Bid to cleaved Bid (tBid) resulting in Bax- (Bcl-2-like protein 4) and BAK-mediated (Bcl-2 homologous antagonist/killer) mitochondrial outer membrane permeabilization (MOMP) and Cytochrome C release from mitochondria. Cytochrome C binds to apoptotic peptidase activating factor-1 (APAF-1) releasing its auto-inhibitory hold. APAF-1 oligomerizes to form a wheel-like structure called the apoptosome which activates caspase 9. Caspase 9 in turn activates the effector caspases (caspase 3/7) to induce apoptosis. In certain cells, when caspase-8 is inhibited, the cell switches to an alternative form of cell death termed necroptosis. For necroptosis to occur, RIPK1, RIPK3 and mixed lineage domain like (MLKL) form the necrosome. RIPK3 phospho-activates MLKL, leading to its oligomerization and translocation to the cell membrane to induce pore opening and oncolysis. cFLIP: cellular FLICE-like inhibitory protein.
Figure 1 Tumor necrosis factor (TNF) receptor-mediated cell death. TNF binding to TNF receptor (TNFR) results in the formation of complex I which includes TNFR-associated death domain (TRADD), receptor interacting protein kinase-1 (RIPK1), TNFR-associated factor 2 (TRAF2), cellular inhibitor of apoptosis 1 (cIAP1), cellular inhibitor of apoptosis 2 (cIAP2) and linear ubiquitin chain assembly complex (LUBAC). RIPK1 is ubiquitinated resulting in the formation of a platform and recruitment of the IκB kinase (IKK) complex (NFκB Essential Modulator (NEMO), IKK1 and IKK2) and TAB (TAK1-binding protein)/TAK-1 (transforming growth factor-β-activated kinase 1) complexes. This results in the activation of NFκB and mitogen-activated protein kinase (MAPK). For apoptosis to occur, the cytoplasmic Complex II is formed which can have two forms. Complex IIa is made up of TRADD, FADD (fas-associated protein with death domain) and caspase-8 and complex IIb consists of RIPK1/RIPK3, FADD, caspase 8 and FLICE-like inhibitory protein long form (FLIPL). Complex II leads to caspase-8-mediated activation of caspase 3/7 and apoptosis in type I cells such as lymphocytes. In type II cells such as hepatocytes, caspase 8 mediates cleavage of Bid to cleaved Bid (tBid) resulting in Bax- (Bcl-2-like protein 4) and BAK-mediated (Bcl-2 homologous antagonist/killer) mitochondrial outer membrane permeabilization (MOMP) and Cytochrome C release from mitochondria. Cytochrome C binds to apoptotic peptidase activating factor-1 (APAF-1) releasing its auto-inhibitory hold. APAF-1 oligomerizes to form a wheel-like structure called the apoptosome which activates caspase 9. Caspase 9 in turn activates the effector caspases (caspase 3/7) to induce apoptosis. In certain cells, when caspase-8 is inhibited, the cell switches to an alternative form of cell death termed necroptosis. For necroptosis to occur, RIPK1, RIPK3 and mixed lineage domain like (MLKL) form the necrosome. RIPK3 phospho-activates MLKL, leading to its oligomerization and translocation to the cell membrane to induce pore opening and oncolysis. cFLIP: cellular FLICE-like inhibitory protein.CC BY · PubMed Central
Figure 2 Drugs or toxic metabolites can cause intrinsic predictable toxicity by binding to intracellular proteins, generating reactive oxygen species (ROS) and inducing organelle stress. If the stress is minor, organelle adaptive responses (such as the unfolded protein responses in the ER or mitochondria) will compensate and adapt and the injury will be dampened. If these responses are overwhelmed, cell death follows. Most drugs cause an idiosyncratic and immune-mediated injury which is HLA-associated and only occurs in individuals with the susceptible HLA polymorphism. Due to the process of adaptation and the liver’s inherent capacity for immune tolerance, most individuals exposed to a toxic drug even in the presence of a susceptible HLA polymorphism will experience mild and transient injury or no injury at all. In a minority of individuals, failure of adaptation results in persistent and severe injury.
Figure 2 Drugs or toxic metabolites can cause intrinsic predictable toxicity by binding to intracellular proteins, generating reactive oxygen species (ROS) and inducing organelle stress. If the stress is minor, organelle adaptive responses (such as the unfolded protein responses in the ER or mitochondria) will compensate and adapt and the injury will be dampened. If these responses are overwhelmed, cell death follows. Most drugs cause an idiosyncratic and immune-mediated injury which is HLA-associated and only occurs in individuals with the susceptible HLA polymorphism. Due to the process of adaptation and the liver’s inherent capacity for immune tolerance, most individuals exposed to a toxic drug even in the presence of a susceptible HLA polymorphism will experience mild and transient injury or no injury at all. In a minority of individuals, failure of adaptation results in persistent and severe injury.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 164

  1. McQueen, C. (2017). Clinical considerations of drug-induced hepatotoxicity. Comprehensive Toxicology, Elsevier. [3rd ed.].
  2. Yuan, 2013, Mechanisms of drug-induced liver injury, Clin. Liver Dis., 17, 507, 10.1016/j.cld.2013.07.002 · DOI · Paper page
  3. Dara, L., Han, D., and Kaplowitz, N. (2012). Mechanisms of Cell Death and Relevance to Drug Toxicity, Academic Press (an imprint of Elsevier). [3rd ed.]. · DOI
  4. Larson, 2005, Acetaminophen-induced acute liver failure: Results of a united states multicenter, prospective study, Hepatology, 42, 1364, 10.1002/hep.20948 · DOI · Paper page
  5. Nathwani, 2006, Drug hepatotoxicity, Clin. Liver Dis., 10, 207, 10.1016/j.cld.2006.05.009 · DOI
  6. Senior, 2007, Drug hepatotoxicity from a regulatory perspective, Clin. Liver Dis., 11, 507, 10.1016/j.cld.2007.06.002 · DOI
  7. Kaplowitz, 2015, Targeting signal transduction pathways which regulate necrosis in acetaminophen hepatotoxicity, J. Hepatol., 63, 5, 10.1016/j.jhep.2015.02.050 · DOI
  8. Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
  9. Denk, 2002, Drug-induced liver injury, Verh. Dtsch. Ges. Pathol., 86, 120
  10. Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
  11. Kaplowitz, 2013, Avoiding idiosyncratic DILI: Two is better than one, Hepatology, 58, 15, 10.1002/hep.26295 · DOI
  12. Bell, 2009, Epidemiology of idiosyncratic drug-induced liver injury, Semin. Liver Dis., 29, 337, 10.1055/s-0029-1240002 · DOI
  13. Ding, W.X., and Yin, X.M. (2017). Cell death in drug induced liver injury. Cell Death in Liver Disease, Springer. · DOI
  14. DeLeve, 1997, Sinusoidal endothelial cells as a target for acetaminophen toxicity: Direct action versus requirement for hepatocyte activation in different mouse strains, Biochem. Pharmacol., 53, 1339, 10.1016/S0006-2952(97)00048-8 · DOI
  15. DeLeve, 1996, Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease, Hepatology, 23, 589, 10.1002/hep.510230326 · DOI
  16. Guicciardi, 2009, Life and death by death receptors, FASEB J., 23, 1625, 10.1096/fj.08-111005 · DOI
  17. Tian, 2013, Natural killer cells in liver disease, Hepatology, 57, 1654, 10.1002/hep.26115 · DOI · Paper page
  18. Protzer, 2012, Living in the liver: Hepatic infections, Nat. Rev. Immunol., 12, 201, 10.1038/nri3169 · DOI · Paper page
  19. Ashkenazi, 2014, Regulated cell death: Signaling and mechanisms, Annu. Rev. Cell Dev. Biol., 30, 337, 10.1146/annurev-cellbio-100913-013226 · DOI · Paper page
  20. Karin, 2002, NFκB at the crossroads of life and death, Nat. Immunol., 3, 221, 10.1038/ni0302-221 · DOI · Paper page
  21. Micheau, 2001, NFκB signals induce the expression of c-flip, Mol. Cell. Biol., 21, 5299, 10.1128/MCB.21.16.5299-5305.2001 · DOI · Paper page
  22. Nagai, 2002, Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-α-induced apoptosis in cultured mouse hepatocytes, Hepatology, 36, 55, 10.1053/jhep.2002.33995 · DOI
  23. Pierce, 2000, Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line, Am. J. Pathol., 157, 221, 10.1016/S0002-9440(10)64533-6 · DOI
  24. Lou, 2007, Glutathione depletion down-regulates tumor necrosis factor α-induced NFκB activity via IκB kinase-dependent and -independent mechanisms, J. Biol. Chem., 282, 29470, 10.1074/jbc.M706145200 · DOI
  25. Han, 2006, Hydrogen peroxide and redox modulation sensitize primary mouse hepatocytes to TNF-induced apoptosis, Free Radic. Biol. Med., 41, 627, 10.1016/j.freeradbiomed.2006.05.002 · DOI
  26. Kim, 2005, Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on APAF-1, Proc. Natl. Acad. Sci. USA, 102, 17545, 10.1073/pnas.0507900102 · DOI · Paper page
  27. Zou, 1997, APAF-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3, Cell, 90, 405, 10.1016/S0092-8674(00)80501-2 · DOI · Paper page
  28. Acehan, 2002, Three-dimensional structure of the apoptosome: Implications for assembly, procaspase-9 binding, and activation, Mol. Cell, 9, 423, 10.1016/S1097-2765(02)00442-2 · DOI · Paper page
  29. Bratton, 2010, Regulation of the APAF-1-caspase-9 apoptosome, J. Cell Sci., 123, 3209, 10.1242/jcs.073643 · DOI · Paper page
  30. Newton, 2016, Necroptosis and inflammation, Annu. Rev. Biochem., 85, 743, 10.1146/annurev-biochem-060815-014830 · DOI
  31. Sun, 2012, Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase, Cell, 148, 213, 10.1016/j.cell.2011.11.031 · DOI · Paper page
  32. Wang, 2014, Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3, Mol. Cell, 54, 133, 10.1016/j.molcel.2014.03.003 · DOI
  33. Gunther, 2016, The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis, J. Clin. Investig., 126, 4346, 10.1172/JCI87545 · DOI · Paper page
  34. Afonso, 2015, Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis, Clin. Sci., 129, 721, 10.1042/CS20140732 · DOI
  35. Dara, 2016, Questions and controversies: The role of necroptosis in liver disease, Cell Death Discov., 2, 16089, 10.1038/cddiscovery.2016.89 · DOI
  36. Newton, 2014, Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis, Science, 343, 1357, 10.1126/science.1249361 · DOI · Paper page
  37. Degterev, 2014, Assays for necroptosis and activity of RIP kinases, Methods Enzymol., 545, 1, 10.1016/B978-0-12-801430-1.00001-9 · DOI
  38. Sun, 1999, RIP3, a novel apoptosis-inducing kinase, J. Biol. Chem., 274, 16871, 10.1074/jbc.274.24.16871 · DOI
  39. Kasof, 2000, The RIP-like kinase, RIP3, induces apoptosis and NFκB nuclear translocation and localizes to mitochondria, FEBS Lett., 473, 285, 10.1016/S0014-5793(00)01473-3 · DOI
  40. Dara, 2015, Receptor interacting protein kinase 1 mediates murine acetaminophen toxicity independent of the necrosome and not through necroptosis, Hepatology, 62, 1847, 10.1002/hep.27939 · DOI
  41. An, 2013, ARC is a novel therapeutic approach against acetaminophen-induced hepatocellular necrosis, J. Hepatol., 58, 297, 10.1016/j.jhep.2012.10.002 · DOI
  42. Ramachandran, 2013, Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice, Hepatology, 58, 2099, 10.1002/hep.26547 · DOI · Paper page
  43. Deutsch, 2015, Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury, Cell Death Dis., 6, e1759, 10.1038/cddis.2015.126 · DOI
  44. Ni, 2012, Activation of autophagy protects against acetaminophen-induced hepatotoxicity, Hepatology, 55, 222, 10.1002/hep.24690 · DOI · Paper page
  45. Aglietti, R.A., and Dueber, E.C. (2017). Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions. Trends Immunol. · DOI
  46. Shi, 2015, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death, Nature, 526, 660, 10.1038/nature15514 · DOI · Paper page
  47. Cao, 2016, Mechanisms of ferroptosis, Cell. Mol. Life Sci., 73, 2195, 10.1007/s00018-016-2194-1 · DOI · Paper page
  48. Dixon, 2012, Ferroptosis: An iron-dependent form of nonapoptotic cell death, Cell, 149, 1060, 10.1016/j.cell.2012.03.042 · DOI · Paper page
  49. Monshi, 2013, Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury, Hepatology, 57, 727, 10.1002/hep.26077 · DOI · Paper page
  50. Tsutsui, 1992, Drug-specific T cells derived from patients with drug-induced allergic hepatitis, J. Immunol., 149, 706, 10.4049/jimmunol.149.2.706 · DOI
  51. Dara, 2015, Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications, Liver Int., 36, 158, 10.1111/liv.12988 · DOI
  52. Lauschke, V.M., and Ingelman-Sundberg, M. (2016). The importance of patient-specific factors for hepatic drug response and toxicity. Int. J. Mol. Sci., 17. · DOI
  53. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: The dilin prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  54. Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat. Genet., 41, 816, 10.1038/ng.379 · DOI · Paper page
  55. Wuillemin, 2013, HLA haplotype determines hapten or p-i t cell reactivity to flucloxacillin, J. Immunol., 190, 4956, 10.4049/jimmunol.1202949 · DOI
  56. Bhogaraju, 1999, Diclofenac-associated hepatitis, South. Med. J., 92, 711, 10.1097/00007611-199907000-00011 · DOI
  57. Mallal, 2008, HLA-B*5701 screening for hypersensitivity to abacavir, N. Engl. J. Med., 358, 568, 10.1056/NEJMoa0706135 · DOI
  58. Hautekeete, 1999, HLA association of amoxicillin-clavulanate--induced hepatitis, Gastroenterology, 117, 1181, 10.1016/S0016-5085(99)70404-X · DOI · Paper page
  59. Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J., 8, 186, 10.1038/sj.tpj.6500458 · DOI
  60. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
  61. Sharma, 2002, Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment, Am. J. Respir. Crit. Care Med., 166, 916, 10.1164/rccm.2108091 · DOI · Paper page
  62. Chen, 2015, The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: A case-control study, J. Clin. Pharm. Ther., 40, 110, 10.1111/jcpt.12211 · DOI
  63. Petros, 2017, HLA-B*57 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in ethiopians, Front. Pharmacol., 8, 90, 10.3389/fphar.2017.00090 · DOI
  64. Spraggs, 2011, HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J. Clin. Oncol., 29, 667, 10.1200/JCO.2010.31.3197 · DOI
  65. Urban, T.J., Nicoletti, P., Chalasani, N., Serrano, J., Stolz, A., Daly, A., Aithal, G., Dillon, J., Navarro, V., and Odin, J. (2017). Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. J. Hepatol. · DOI · Paper page
  66. Nicoletti, 2017, Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study, Gastroenterology, 152, 1078, 10.1053/j.gastro.2016.12.016 · DOI · Paper page
  67. Phillips, 2013, Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in south africa, J. Acquir. Immune Defic. Syndr., 62, e55, 10.1097/QAI.0b013e31827ca50f · DOI
  68. Uetrecht, 2008, Idiosyncratic drug reactions: Past, present, and future, Chem. Res. Toxicol., 21, 84, 10.1021/tx700186p · DOI · Paper page
  69. Saito, 2015, Predictive genomic markers for severe adverse drug reactions, Yakugaku Zasshi, 135, 589, 10.1248/yakushi.14-00249-3 · DOI
  70. Nicoletti, 2016, HLA-DRB1*16:01-DQB1*05:02 is a novel genetic risk factor for flupirtine-induced liver injury, Pharmacogenet. Genom., 26, 218, 10.1097/FPC.0000000000000209 · DOI
  71. Berson, 1994, Possible role of HLA in hepatotoxicity: An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis, J. Hepatol., 20, 336, 10.1016/S0168-8278(94)80004-9 · DOI
  72. Daly, 2009, Genetic association studies in drug-induced liver injury, Semin. Liver Dis., 29, 400, 10.1055/s-0029-1240009 · DOI
  73. Russmann, 2005, Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK general practice research database, Br. J. Clin. Pharmacol., 60, 76, 10.1111/j.1365-2125.2005.02370.x · DOI · Paper page
  74. Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat. Genet., 42, 711, 10.1038/ng.632 · DOI · Paper page
  75. Xu, 2016, HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer, Clin. Cancer Res., 22, 1371, 10.1158/1078-0432.CCR-15-2044 · DOI
  76. Hirata, 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in japanese patients: A preliminary case-control study, Pharmacogenom. J., 8, 29, 10.1038/sj.tpj.6500442 · DOI
  77. Kurosaki, 2000, HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin, Dig. Dis. Sci., 45, 1103, 10.1023/A:1005585515826 · DOI
  78. Andrade, 2005, Drug-induced liver injury: An analysis of 461 incidences submitted to the spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
  79. Bjornsson, 2015, Drug-induced liver injury: An overview over the most critical compounds, Arch. Toxicol., 89, 327, 10.1007/s00204-015-1456-2 · DOI
  80. Bessone, F., Hernandez, N., Lucena, M.I., Andrade, R.J., Latin DILI Network, and Spanish DILI Registry (2016). The Latin American DILI registry experience: A successful ongoing collaborative strategic initiative. Int. J. Mol. Sci., 17. · DOI
  81. Takikawa, 2009, Drug-induced liver injury in japan: An analysis of 1676 cases between 1997 and 2006, Hepatol. Res., 39, 427, 10.1111/j.1872-034X.2008.00486.x · DOI · Paper page
  82. Roth, 2017, Idiosyncratic drug-induced liver injury: Is drug-cytokine interaction the linchpin?, J. Pharmacol. Exp. Ther., 360, 461, 10.1124/jpet.116.237578 · DOI
  83. Kusters, 1996, Interferon γ plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A, Gastroenterology, 111, 462, 10.1053/gast.1996.v111.pm8690213 · DOI
  84. Morita, 1995, Protective effect of hepatocyte growth factor on interferon-γ-induced cytotoxicity in mouse hepatocytes, Hepatology, 21, 1585
  85. Vodovotz, 2004, Inflammatory modulation of hepatocyte apoptosis by nitric oxide: In vivo, in vitro, and in silico studies, Curr. Mol. Med., 4, 753, 10.2174/1566524043359944 · DOI
  86. Nagaki, 1994, Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B, Gastroenterology, 106, 450, 10.1016/0016-5085(94)90604-1 · DOI
  87. Gantner, 1995, Tumor necrosis factor-induced hepatic DNA fragmentation as an early marker of T cell-dependent liver injury in mice, Gastroenterology, 109, 166, 10.1016/0016-5085(95)90282-1 · DOI
  88. Gantner, 1995, Concanavalin A-induced T-cell-mediated hepatic injury in mice: The role of tumor necrosis factor, Hepatology, 21, 190
  89. Tiegs, 1992, A T cell-dependent experimental liver injury in mice inducible by concanavalin a, J. Clin. Investig., 90, 196, 10.1172/JCI115836 · DOI · Paper page
  90. Leist, 1997, Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins, Gastroenterology, 112, 923, 10.1053/gast.1997.v112.pm9041255 · DOI
  91. Dara, 2016, A murder mystery in the liver: Who done it and how?, J. Clin. Investig., 126, 4068, 10.1172/JCI90830 · DOI
  92. Suda, 2016, Knockdown of RIPK1 markedly exacerbates murine immune-mediated liver injury through massive apoptosis of hepatocytes, independent of necroptosis and inhibition of nf-kappab, J. Immunol., 197, 3120, 10.4049/jimmunol.1600690 · DOI
  93. Filliol, 2016, RIPK1 protects from TNF-α-mediated liver damage during hepatitis, Cell Death Dis., 7, e2462, 10.1038/cddis.2016.362 · DOI
  94. Bultemann, 2001, Degeneracy and additional alloreactivity of drug-specific human αβ+ T cell clones, Int. Immunol., 13, 877, 10.1093/intimm/13.7.877 · DOI
  95. Zanni, 1999, Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human αβ+ T cell clones, J. Immunol., 162, 595, 10.4049/jimmunol.162.1.595 · DOI
  96. Pichler, 2002, Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept, Curr. Opin. Allergy Clin. Immunol., 2, 301, 10.1097/00130832-200208000-00003 · DOI
  97. Grove, 2015, Human leukocyte antigen genetic risk factors of drug-induced liver toxicology, Expert Opin. Drug Metab. Toxicol., 11, 395, 10.1517/17425255.2015.992414 · DOI
  98. Ostrov, 2012, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, Proc. Natl. Acad. Sci. USA, 109, 9959, 10.1073/pnas.1207934109 · DOI · Paper page
  99. Wei, 2012, Direct interaction between HLA-B and carbamazepine activates T cells in patients with stevens-johnson syndrome, J. Allergy Clin. Immunol., 129, 1562, 10.1016/j.jaci.2011.12.990 · DOI
  100. Li, 2002, A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity, Chem. Biol. Interact., 142, 7, 10.1016/S0009-2797(02)00051-0 · DOI
  101. Ulrich, 2007, Idiosyncratic toxicity: A convergence of risk factors, Annu. Rev. Med., 58, 17, 10.1146/annurev.med.58.072905.160823 · DOI
  102. Ray, 1991, Halothane hepatitis, Br. J. Anaesth., 67, 84, 10.1093/bja/67.1.84 · DOI
  103. Dugan, 2010, A mouse model of severe halothane hepatitis based on human risk factors, J. Pharmacol. Exp. Ther., 333, 364, 10.1124/jpet.109.164541 · DOI
  104. Khouri, 1987, Hepatocanalicular injury associated with vitamin a derivative etretinate. An idiosyncratic hypersensitivity reaction, Dig. Dis. Sci., 32, 1207, 10.1007/BF01300208 · DOI
  105. Fukano, 2000, Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination, Hum. Pathol., 31, 250, 10.1016/S0046-8177(00)80229-4 · DOI
  106. Deng, 2009, Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models, Pharmacol. Rev., 61, 262, 10.1124/pr.109.001727 · DOI
  107. Shaw, 2010, Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity, Toxicol. Sci., 118, 7, 10.1093/toxsci/kfq168 · DOI · Paper page
  108. Mak, 2015, The role of CD8 T cells in amodiaquine-induced liver injury in PD1−/− mice cotreated with anti-CTLA-4, Chem. Res. Toxicol., 28, 1567, 10.1021/acs.chemrestox.5b00137 · DOI
  109. Metushi, 2015, Treatment of PD-1−/− mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients, Hepatology, 61, 1332, 10.1002/hep.27549 · DOI
  110. Calne, 1969, Induction of immunological tolerance by porcine liver allografts, Nature, 223, 472, 10.1038/223472a0 · DOI
  111. Knolle, 2000, Local control of the immune response in the liver, Immunol. Rev., 174, 21, 10.1034/j.1600-0528.2002.017408.x · DOI · Paper page
  112. Adams, 2015, From immunosuppression to tolerance, J. Hepatol., 62, S170, 10.1016/j.jhep.2015.02.042 · DOI
  113. Mitchell, 1975, Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy, Chest, 68, 181, 10.1378/chest.68.2.181 · DOI
  114. Uetrecht, 2015, Inhibition of immune tolerance unmasks drug-induced allergic hepatitis, Hepatology, 62, 346, 10.1002/hep.27824 · DOI
  115. Wisse, 1985, The liver sieve: Considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse, Hepatology, 5, 683, 10.1002/hep.1840050427 · DOI
  116. Fraser, 1995, Lipoproteins and the liver sieve: The role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis, Hepatology, 21, 863
  117. Lohse, 1996, Antigen-presenting function and B7 expression of murine sinusoidal endothelial cells and kupffer cells, Gastroenterology, 110, 1175, 10.1053/gast.1996.v110.pm8613007 · DOI · Paper page
  118. Knolle, 1999, Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells, J. Immunol., 162, 1401, 10.4049/jimmunol.162.3.1401 · DOI
  119. Bissell, 1995, Cell-specific expression of transforming growth factor-β in rat liver. Evidence for autocrine regulation of hepatocyte proliferation, J. Clin. Investig., 96, 447, 10.1172/JCI118055 · DOI · Paper page
  120. Knolle, 1998, Interleukin-10 expression is autoregulated at the transcriptional level in human and murine kupffer cells, Hepatology, 27, 93, 10.1002/hep.510270116 · DOI
  121. Knolle, 1995, Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge, J. Hepatol., 22, 226, 10.1016/0168-8278(95)80433-1 · DOI · Paper page
  122. Rieder, 1990, Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor: Comparison with umbilical vein endothelial cells, J. Hepatol., 11, 359, 10.1016/0168-8278(90)90222-D · DOI
  123. Dieter, 1987, Prostaglandin release but not superoxide production by rat Kupffer cells stimulated in vitro depends on Na+/H+ exchange, Eur. J. Biochem., 170, 201, 10.1111/j.1432-1033.1987.tb13687.x · DOI
  124. Mak, 2017, Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury, J. Immunotoxicol., 14, 89, 10.1080/1547691X.2017.1290716 · DOI
  125. Lee, 2004, Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure, Hepatology, 40, 6, 10.1002/hep.20293 · DOI · Paper page
  126. Major, 2016, Trends in rates of acetaminophen-related adverse events in the United States, Pharmacoepidemiol. Drug Saf., 25, 590, 10.1002/pds.3906 · DOI
  127. Nourjah, 2006, Estimates of acetaminophen (paracetomal)-associated overdoses in the United States, Pharmacoepidemiol. Drug Saf., 15, 398, 10.1002/pds.1191 · DOI · Paper page
  128. Rowden, 2005, Updates on acetaminophen toxicity, Med. Clin. N. Am., 89, 1145, 10.1016/j.mcna.2005.06.009 · DOI
  129. Prescott, 1974, Gastrointestinal absorption of drugs, Med. Clin. N. Am., 58, 907, 10.1016/S0025-7125(16)32088-0 · DOI
  130. Josting, 1976, Glucuronidation of paracetamol, morphine and 1-naphthol in the rat intestinal loop, Biochem. Pharmacol., 25, 613, 10.1016/0006-2952(76)90399-3 · DOI
  131. Mitchell, 1973, Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism, J. Pharmacol. Exp. Ther., 187, 185, 10.1016/S0022-3565(25)29663-X · DOI · Paper page
  132. Mitchell, 1974, Acetaminophen-induced hepatic injury: Protective role of glutathione in man and rationale for therapy, Clin. Pharmacol. Ther., 16, 676, 10.1002/cpt1974164676 · DOI · Paper page
  133. Kulkens, 1986, Paracetamol, 3-monoalkyl- and 3,5-dialkyl derivatives: Comparison of their microsomal cytochrome P-450 dependent oxidation and toxicity in freshly isolated hepatocytes, Biochem. Pharmacol., 35, 3693, 10.1016/0006-2952(86)90653-2 · DOI
  134. Moldeus, 1978, Paracetamol metabolism and toxicity in isolated hepatocytes from rat and mouse, Biochem. Pharmacol., 27, 2859, 10.1016/0006-2952(78)90201-0 · DOI
  135. Gibson, 1996, Mechanism of acetaminophen-induced hepatotoxicity: Covalent binding versus oxidative stress, Chem. Res. Toxicol., 9, 580, 10.1021/tx950153d · DOI
  136. Pumford, 1990, Immunoblot analysis of protein containing 3-(cystein-S-yl) acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice, Toxicol. Appl. Pharmacol., 104, 521, 10.1016/0041-008X(90)90174-S · DOI
  137. Szkolnicka, 2016, Reducing hepatocyte injury and necrosis in response to paracetamol using noncoding RNAs, Stem Cells Transl. Med., 5, 764, 10.5966/sctm.2015-0117 · DOI
  138. Jaeschke, 2011, Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts, J. Gastroenterol. Hepatol., 26, 173, 10.1111/j.1440-1746.2010.06592.x · DOI
  139. Gujral, 2002, Mode of cell death after acetaminophen overdose in mice: Apoptosis or oncotic necrosis?, Toxicol. Sci., 67, 322, 10.1093/toxsci/67.2.322 · DOI · Paper page
  140. Jaeschke, 2004, Apoptosis and necrosis in liver disease, Liver Int., 24, 85, 10.1111/j.1478-3231.2004.0906.x · DOI
  141. Lawson, 1999, Inhibition of Fas receptor (CD95)-induced hepatic caspase activation and apoptosis by acetaminophen in mice, Toxicol. Appl. Pharmacol., 156, 179, 10.1006/taap.1999.8635 · DOI
  142. Bajt, 2006, Nuclear translocation of endonuclease G and apoptosis-inducing factor during acetaminophen-induced liver cell injury, Toxicol. Sci., 94, 217, 10.1093/toxsci/kfl077 · DOI
  143. Jaeschke, 2011, No evidence for caspase-dependent apoptosis in acetaminophen hepatotoxicity, Hepatology, 53, 718, 10.1002/hep.23940 · DOI
  144. Sharma, 2012, Critical role for mixed-lineage kinase 3 in acetaminophen-induced hepatotoxicity, Mol. Pharmacol., 82, 1001, 10.1124/mol.112.079863 · DOI
  145. Nakagawa, 2008, Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation, Gastroenterology, 135, 1311, 10.1053/j.gastro.2008.07.006 · DOI
  146. Gunawan, 2006, c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity, Gastroenterology, 131, 165, 10.1053/j.gastro.2006.03.045 · DOI · Paper page
  147. Huo, 2017, Antcin h protects against acute liver injury through disruption of the interaction of c-Jun N-terminal kinase with mitochondria, Antioxid. Redox Signal., 26, 207, 10.1089/ars.2016.6833 · DOI
  148. Win, 2016, c-Jun N-terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)-dependent pathway leading to inactivation of intramitochondrial Src, Hepatology, 63, 1987, 10.1002/hep.28486 · DOI
  149. Uzi, 2013, Chop is a critical regulator of acetaminophen-induced hepatotoxicity, J. Hepatol., 59, 495, 10.1016/j.jhep.2013.04.024 · DOI
  150. Kon, 2004, Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes, Hepatology, 40, 1170, 10.1002/hep.20437 · DOI · Paper page
  151. Masubuchi, 2005, Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice, J. Hepatol., 42, 110, 10.1016/j.jhep.2004.09.015 · DOI · Paper page
  152. Ramachandran, 2011, Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury, Free Radic. Res., 45, 156, 10.3109/10715762.2010.520319 · DOI
  153. Loguidice, 2011, Acetaminophen overdose-induced liver injury in mice is mediated by peroxynitrite independently of the cyclophilin d-regulated permeability transition, Hepatology, 54, 969, 10.1002/hep.24464 · DOI
  154. Lin, 2016, Advances in engineered liver models for investigating drug-induced liver injury, BioMed Res. Int., 2016, 1829148, 10.1155/2016/1829148 · DOI · Paper page
  155. Porceddu, 2012, Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria, Toxicol. Sci., 129, 332, 10.1093/toxsci/KFS197 · DOI
  156. Khetani, 2008, Microscale culture of human liver cells for drug development, Nat. Biotechnol., 26, 120, 10.1038/nbt1361 · DOI · Paper page
  157. Funakoshi, 2014, Human induced pluripotent stem cells in hepatology: Beyond the proof of concept, Am. J. Pathol., 184, 332, 10.1016/j.ajpath.2013.09.026 · DOI
  158. Teschke, R., Schulze, J., Eickhoff, A., and Danan, G. (2017). Drug induced liver injury: Can biomarkers assist RUCAM in causality assessment?. Int. J. Mol. Sci., 18. · DOI
  159. Fontana, 2009, Drug-induced liver injury network (DILIN) prospective study: Rationale, design and conduct, Drug Saf., 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
  160. Lucena, 2001, Comparison of two clinical scales for causality assessment in hepatotoxicity, Hepatology, 33, 123, 10.1053/jhep.2001.20645 · DOI · Paper page
  161. Danan, G., and Teschke, R. (2016). Rucam in drug and herb induced liver injury: The update. Int. J. Mol. Sci., 17. · DOI · Paper page
  162. Kaplowitz, 2001, Causality assessment versus guilt-by-association in drug hepatotoxicity, Hepatology, 33, 308, 10.1053/jhep.2001.21083 · DOI
  163. Chen, 2015, Drug-induced liver injury: Interactions between drug properties and host factors, J. Hepatol., 63, 503, 10.1016/j.jhep.2015.04.016 · DOI · Paper page
  164. Russmann, 2009, Current concepts of mechanisms in drug-induced hepatotoxicity, Curr. Med. Chem., 16, 3041, 10.2174/092986709788803097 · DOI

Cited by

Metadata

Authors
Iorga, A., Dara, L., & Kaplowitz, N.
Affiliations
Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
ORCID
Dara, Lily
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2017-05-09
Volume
18
Issue
5
Pages
1018
ISSN
1422-0067
DOI
10.3390/ijms18051018
PMC
PMC5454931
Cited by
268
References
19
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (K08DK109141, R01DK067215, P30DK048522)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.